You searched for: asat (Engelska - Maltesiska)

(formerly c/o asat trust reg.).
(formalment c/o asat trust reg.).

hepatic enzyme increased (including ggt, alat, asat)
dermatite tal- kuntatt,

asat increased blood pressure increased blood ldh increased blood glucose increased
Żjieda f’ asat Żjieda fil- pressjoni tad- demm Żjieda fl- ldh fid- demm Żjieda fil- glucose fid- demm

increased alat/ asat monitoring should be considered in these patients.
monitoraġġ aktar ta 'spiss għal alat/ asat għandu jiġi kkonsidrat f' dawn il- pazjenti.

increase in liver enzyme levels (asat, alat, ap).
Żieda fil- livelli ta ’ l- enzimi tal- fwied (asat, alat, ap).

if asat or alat increase to > 5 uln during treatment, nevirapine should be immediately stopped.
jekk waqt il-kura l-għadd asat jew alat jiżdied għal > 5 uln, nevirapine irid jiġi mwaqqaf minnufih.

very common: increase in liver enzyme levels (asat, alat, ap).
komuni ħafna: Żieda fil-livelli tal-enzimi tal-fwied (asat, alat, ap).

aptivus therapy should be discontinued in patients experiencing asat or alat elevations greater than 10x uln, or developing signs or symptoms of clinical hepatitis during therapy.
it- terapija b' aptivus għandha tiġi mwaqqfa meta l- pazjenti jkollhom żjidiet fl- asat jew l- alat ta 'aktar minn 10x l- uln, jew meta jiżviluppaw sinjali jew sintomi ta' epatite klinika waqt it- trattament.

multivariate analyses showed that baseline alat or asat above daids grade 1 and co-infection with hepatitis b or c were risk factors for these elevations.
analiżi multivarjati wrew li l- livell bażi ta 'riferiment ta' alat jew asat 'il fuq minn grad 1 ta' daids u ko- infezzjoni b' epatite b jew Ċ kienu fatturi ta 'predispożizzjoni għal dawn iż- żidiet.

if asat or alat > 2.5 uln before or during treatment, then liver tests should be monitored more frequently during regular clinic visits.
jekk l- għadd asat jew alat > 2. 5 uln qabel jew waqt it- trattament, it- testijiet ta 'fwied iridu jiġu sorveljati aktar ta' spiss waqt il- visti regolari fil- klinika.

viramune must not be readministered in patients who previously had asat or alat > 5 uln during viramune therapy and had recurrence of liver function abnormalities upon readministration of viramune (see section 4.4).
viramune m’ għandux jerġa jingħata lill- pazjenti li kellhom asat jew alat > 5 uln waqt terapija b’ viramune, u li kellhom mill- ġdid abnormalitàjiet fil- funzjoni tal- fwied meta reġgħu ngħataw viramune (ara sezzjoni 4. 4).